Dental Bone Graft Substitute Market Size, Share, & Trends Analysis | Global | 2026-2032 | MedCore | Includes: Allografts, Xenografts, and Synthetic Grafts

Product Description

Overall, the global dental bone graft substitute market was valued at $1.19 billion in 2025. This is expected to increase over the forecast period at a CAGR of 7.3% to reach nearly $1.95 billion.

The full report suite on the global market for dental bone graft substitutes (DBGSs) includes segments for allografts, xenografts and synthetic DBGS products.

Data Types Included

• Unit Sales, Average Selling Prices, Market Size & Growth Trends
• Market Drivers & Limiters
• Market Forecasts Until 2032, and Historical Data to 2022
• Recent Mergers & Acquisitions
• Company Profiles and Product Portfolios
• Leading Competitors

Global Dental Bone Graft Substitute Market Market Trends

Growth in the biologically derived DBGS segment, including allografts and xenografts, is expected to remain an important market trend over the forecast period. Advances in tissue processing, sterilization and traceability have significantly reduced concerns related to disease transmission, contributing to improved clinician and patient acceptance of biologic graft materials. Regulatory authorities and tissue banks have implemented more rigorous quality and safety standards, enabling manufacturers to secure approvals in multiple markets and expand international distribution. Despite these advancements, adoption remains influenced by regional regulatory environments, cultural considerations and supply limitations. As a result, while biologically derived DBGS products are expected to continue gaining acceptance globally, their growth trajectory will vary by region and remain balanced by increasing competition from synthetic alternatives.

Global Dental Bone Graft Substitute Market Market Share Insights

• Geistlich remained the leading competitor in the global dental bone graft substitute (DBGS) market in 2025, driven primarily by its strong position in the xenograft segment, which continues to account for a substantial share of global DBGS usage outside of North America. Xenografts are widely preferred in many regions due to their availability, consistent quality and established clinical performance, factors that have supported Geistlich’s sustained market leadership. The company’s Bio-Oss® bovine xenograft portfolio is widely regarded as the clinical reference standard in this segment, supported by extensive long-term clinical evidence and global adoption. Geistlich has continued to refine and expand its Bio-Oss® offerings, including the availability of smaller-volume formats designed to address narrow defects and minor augmentation procedures, enhancing procedural flexibility for clinicians. Beyond xenografts, Geistlich has diversified its regenerative portfolio across multiple biomaterials categories, reinforcing its competitive presence in the broader dental biomaterials market. The company’s continued focus on biologically driven regeneration and specialization in bone and tissue healing remains central to its growth strategy and competitive positioning over the forecast period.
• Henry Schein was the second-leadingcompetitor in the DBGS market in 2025 through its subsidiary BioHorizons. BioHorizons offers a diversified regenerative portfolio that includes MinerOss®, Grafton® DBM and LADDEC® graft materials. The MinerOss® line includes cortical, cancellous and cortico-cancellous allografts used in various regenerative procedures, while Grafton® DBM products remain widely utilized in periodontal, sinus and ridge augmentation applications. Through BioHorizons and its affiliated regenerative biomaterials business ACE Southern, Henry Schein participates across multiple graft material categories, including allografts, xenografts and synthetic substitutes, supporting its presence in the broader regenerative dentistry market.
• ZimVie was the third-leading competitor in the global DBGS market in 2025. Following the 2022 spin-off from Zimmer Biomet, the company maintained a strong position through a diversified portfolio that includes Puros® allografts, RegenerOss® graft materials, Endobon® xenografts and IngeniOs® synthetic graft substitutes. The Puros® line remains a key contributor, particularly within the mineralized allograft segment. In 2025, ZimVie was acquired by ARCHIMED, positioning the company for continued expansion in the dental implant and biomaterials markets. North America represents the largest share of ZimVie’s DBGS revenue due to strong clinical adoption of allograft materials in the region.

Global Dental Bone Graft Substitute Market Market Segmentation Summary

• Dental Bone Graft Substitute Market – Further Segmented Into:
  • Type: Allograft, Xenograft, and Synthetic.
  • Application*: Socket Preservation, Sinus Augmentation, Ridge Augmentation, Periodontal Procedure.

Research Scope Summary